MA28080A1 - Derives de tropane a substituant imidazopyridine ayant une activite antagoniste des recepteurs ccr5, pour le traitement de l'infection par le vih et de l'inflammation - Google Patents

Derives de tropane a substituant imidazopyridine ayant une activite antagoniste des recepteurs ccr5, pour le traitement de l'infection par le vih et de l'inflammation

Info

Publication number
MA28080A1
MA28080A1 MA28906A MA28906A MA28080A1 MA 28080 A1 MA28080 A1 MA 28080A1 MA 28906 A MA28906 A MA 28906A MA 28906 A MA28906 A MA 28906A MA 28080 A1 MA28080 A1 MA 28080A1
Authority
MA
Morocco
Prior art keywords
inhibitors
treatment
combination
additional therapeutic
imidazopyridine
Prior art date
Application number
MA28906A
Other languages
English (en)
Inventor
Paul Anthony Stupple
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0323236.0A external-priority patent/GB0323236D0/en
Priority claimed from GB0325020A external-priority patent/GB0325020D0/en
Priority claimed from GB0418566A external-priority patent/GB0418566D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA28080A1 publication Critical patent/MA28080A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)

Abstract

20. Association d'un composé de formule (I) telle que définie dans l'une quelconque des revendications 1 à 7, ou d'un sel ou produit de solvatation pharmaceutiquement acceptable de ce composé, avec un ou plusieurs agents thérapeutiques supplémentaires. 21. Association suivant la revendication 20, dans laquelle le ou les agents thérapeutiques supplémentaires sont choisis parmi ceux utiles dans le traitement de maladies à médiation par, ou associées à, la modulation des récepteurs CCR5. 22. Association suivant la revendication 21, dans laquelle; le ou les agents thérapeutiques supplémentaires sont choisis parmi ceux utiles dans le traitement contre le VIH. 23. Association suivant l'une quelconque des revendications 20 à 22, dans laquelle le ou les agents thérapeutiques supplémentaires sont choisis entre des inhibiteurs de protéases du VIH, des inhibiteurs de transcriptase inverse et non nucléosidiques, des inhibiteurs de transcriptase inverse nucléosidiques/nucléotidiques, d'autres antagonistes de CCR5, des agents qui inhibent l'interaction de gp120 avec CD4, d'autres agents qui inhibent l'entrée du VIH dans la cellule cible, des inhibiteurs d'intégrase et des inhibiteurs de RNaseH. DEPOSANT Société dite: PFIZER INC. REVENDICATION DE PRIORITES GB 3 Octobre 2003 0323236.0 GB 27 Octobre 2003 0325020.6 GB 19 Août 2004 0418566.6 Voir en annexe le titre de l'invention et le texte de l'abrégé
MA28906A 2003-10-03 2006-04-03 Derives de tropane a substituant imidazopyridine ayant une activite antagoniste des recepteurs ccr5, pour le traitement de l'infection par le vih et de l'inflammation MA28080A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0323236.0A GB0323236D0 (en) 2003-10-03 2003-10-03 Chemical compounds
GB0325020A GB0325020D0 (en) 2003-10-27 2003-10-27 Chemical compounds
GB0418566A GB0418566D0 (en) 2004-08-19 2004-08-19 Tropane derivatives

Publications (1)

Publication Number Publication Date
MA28080A1 true MA28080A1 (fr) 2006-08-01

Family

ID=34426592

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28906A MA28080A1 (fr) 2003-10-03 2006-04-03 Derives de tropane a substituant imidazopyridine ayant une activite antagoniste des recepteurs ccr5, pour le traitement de l'infection par le vih et de l'inflammation

Country Status (35)

Country Link
US (2) US7309790B2 (fr)
EP (1) EP1682545B1 (fr)
JP (1) JP4874107B2 (fr)
KR (1) KR100777885B1 (fr)
AP (1) AP2174A (fr)
AR (1) AR045856A1 (fr)
AT (1) ATE380813T1 (fr)
AU (1) AU2004278158B2 (fr)
BR (1) BRPI0414862A (fr)
CA (1) CA2540834C (fr)
CY (1) CY1107281T1 (fr)
DE (1) DE602004010708T2 (fr)
DK (1) DK1682545T3 (fr)
EA (1) EA009941B1 (fr)
EC (1) ECSP066475A (fr)
ES (1) ES2295924T3 (fr)
GE (1) GEP20084417B (fr)
HN (1) HN2004000383A (fr)
HR (1) HRP20080052T3 (fr)
IL (1) IL174208A0 (fr)
MA (1) MA28080A1 (fr)
MX (1) MXPA06003749A (fr)
MY (1) MY137609A (fr)
NO (1) NO20061978L (fr)
NZ (1) NZ545837A (fr)
OA (1) OA13266A (fr)
PA (1) PA8614301A1 (fr)
PE (1) PE20050961A1 (fr)
PL (1) PL1682545T3 (fr)
PT (1) PT1682545E (fr)
RS (1) RS20060198A (fr)
SI (1) SI1682545T1 (fr)
TW (1) TWI280244B (fr)
UY (1) UY28546A1 (fr)
WO (1) WO2005033107A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7122542B2 (en) 2003-07-30 2006-10-17 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
KR20080108319A (ko) 2006-04-05 2008-12-12 쉐링 코포레이션 약제학적 제형: 8-［｛1-（3,5-비스-（트리플루오로메틸）페닐）-에톡시｝-메틸］-8-페닐-1,7-디아자-스피로［4,5］데칸-2-온의 염 및이를 사용한 치료 방법
WO2008030853A2 (fr) * 2006-09-06 2008-03-13 Incyte Corporation Thérapie de combinaison contre l'infection par le virus de l'immunodéficience humaine
EP2089369B1 (fr) 2006-10-19 2011-02-02 Rigel Pharmaceuticals, Inc. Derives 2,4 -pyrimidinediamine en tant qu'inhibiteurs de kinases jak pour le traitement de maladies autoimmunes
EP2120938A4 (fr) * 2006-12-20 2010-12-08 Merck Sharp & Dohme Analogues de l'imidazopyridine en tant que modulateurs du récepteur de cb2, utilisables pour le traitement de la douleur et des maladies respiratoires et non respiratoires
PE20081891A1 (es) * 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
US8012956B2 (en) * 2007-10-25 2011-09-06 Exelixis, Inc. Tropane compounds
SI2265607T1 (sl) 2008-02-15 2017-06-30 Rigel Pharmaceuticals, Inc. Spojine pirimidin-2-amina in njihova uporaba kot inhibitorji JAK kinaz
ES2546502T3 (es) 2008-04-16 2015-09-24 Portola Pharmaceuticals, Inc. 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
MX336071B (es) 2009-08-14 2016-01-06 Opko Health Inc Formulaciones intravenosas de antagonistas de neurocinina 1.
BR112012024522A2 (pt) 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
EP2975027A1 (fr) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides comme modulateurs de la kinase jak
WO2013024022A1 (fr) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour traiter l'hypertension pulmonaire
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
EP2903970A4 (fr) 2012-10-08 2016-11-30 Portola Pharm Inc Inhibiteurs substitués de pyrimidinyl kinase
AU2014326601B2 (en) * 2013-09-25 2018-01-18 SpecGx LLC Preparation of radioiodinated 3-fluoropropyl-nor-beta-CIT
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
WO2023192360A1 (fr) * 2022-03-31 2023-10-05 Incelldx, Inc. Méthodes de traitement d'un sujet pour une maladie de lyme post-traitement (ptld) et compositions destinées à être utilisées dans celles-ci
WO2023192361A1 (fr) * 2022-03-31 2023-10-05 Incelldx, Inc. Procédés de traitement d'un sujet pour la fibromyalgie et compositions destinées à être utilisées dans ceux-ci

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GEP19991749B (en) 1994-04-19 1999-09-10 Neurosearch As Propane-2-Aldoxine Derivatives as Neurotransmitter Reuptake Inhibitors
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
RU2167876C2 (ru) 1996-02-22 2001-05-27 Ньюросерч А/С 2,3-трансдизамещенное тропановое производное, способ его получения, фармацевтическая композиция
WO2000035296A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Liberation amelioree d'agents medicamenteux actifs par un enrobage de chewing-gum
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
EP1284974B1 (fr) * 2000-05-26 2004-03-03 Pfizer Limited Derives du triazolyltropane utilises comme modulateurs de ccr5
KR100734685B1 (ko) 2002-04-08 2007-07-02 화이자 인코포레이티드 Ｃｃｒ5 조절제로서의 트로판 유도체
US6855724B2 (en) * 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy

Also Published As

Publication number Publication date
EP1682545B1 (fr) 2007-12-12
BRPI0414862A (pt) 2006-11-28
AR045856A1 (es) 2005-11-16
ATE380813T1 (de) 2007-12-15
US20050131011A1 (en) 2005-06-16
ECSP066475A (es) 2006-10-10
UY28546A1 (es) 2005-05-31
NZ545837A (en) 2009-12-24
MXPA06003749A (es) 2006-06-14
AP2006003580A0 (en) 2006-04-30
US20080045563A1 (en) 2008-02-21
WO2005033107A1 (fr) 2005-04-14
DE602004010708T2 (de) 2008-12-04
PL1682545T3 (pl) 2008-04-30
TW200519112A (en) 2005-06-16
MY137609A (en) 2009-02-27
RS20060198A (en) 2008-09-29
CA2540834C (fr) 2010-06-22
PT1682545E (pt) 2008-02-11
ES2295924T3 (es) 2008-04-16
EP1682545A1 (fr) 2006-07-26
EA009941B1 (ru) 2008-04-28
US7790740B2 (en) 2010-09-07
PE20050961A1 (es) 2005-11-29
GEP20084417B (en) 2008-07-10
AU2004278158A1 (en) 2005-04-14
AU2004278158B2 (en) 2009-08-13
HN2004000383A (es) 2008-10-14
OA13266A (en) 2007-01-31
KR20060070571A (ko) 2006-06-23
PA8614301A1 (es) 2005-05-10
KR100777885B1 (ko) 2007-11-28
TWI280244B (en) 2007-05-01
AP2174A (en) 2010-11-20
JP4874107B2 (ja) 2012-02-15
HRP20080052T3 (en) 2008-02-29
NO20061978L (no) 2006-07-03
JP2007507483A (ja) 2007-03-29
CA2540834A1 (fr) 2005-04-14
CY1107281T1 (el) 2012-11-21
DK1682545T3 (da) 2008-03-17
EA200600480A1 (ru) 2006-08-25
SI1682545T1 (sl) 2008-04-30
DE602004010708D1 (de) 2008-01-24
US7309790B2 (en) 2007-12-18
IL174208A0 (en) 2006-08-01

Similar Documents

Publication Publication Date Title
MA28080A1 (fr) Derives de tropane a substituant imidazopyridine ayant une activite antagoniste des recepteurs ccr5, pour le traitement de l'infection par le vih et de l'inflammation
Benton et al. Medical co-morbidity in depressive disorders
MA27190A1 (fr) Derives de tropane servant de modulateurs de ccr5
US20210161991A1 (en) Uses of hypoxia-inducible factor inhibitors
MA50065B1 (fr) Dérivés de composés de spiro[3h-indole-3,2´-pyrrolidine]-2(1h)-one et dérivés utilisés comme inhibiteurs de mdm2-p53
MA28064A1 (fr) Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA31419B1 (fr) Derives de pyridine
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA32306B1 (fr) Derives de quinoleines et de quinoxalines en tant qu'inhibiteurs de proteine tyrosine kinases
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
MA28429B1 (fr) Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
KR20010078803A (ko) 제약 복합제제
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
DE602004020638D1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
MX2022006736A (es) Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas.
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
TW200812589A (en) Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein, interleukin-6, or interferon-gamma levels
Lau et al. Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum
MA27435A1 (fr) DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH
US10906876B2 (en) Tetrahydroisoquinolines as selective NADPH oxidase 2 inhibitors
MA53043A1 (fr) Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation